Skip to main content
. 2024 Apr 25;13(9):2524. doi: 10.3390/jcm13092524

Table 2.

The 5-Year Survival Rate and Median survival time (MST) of the patients with gastric cancer.

5-Year OS (95% CI) MST (Months) (95% CI) p-Value
Male Female Male Female Log-Rank Generalized Wilcoxon
Overall 52.6 (51.7–53.5) 55.3 (53.9–56.7) 69 (65.2–72.8) 86 (76.4–95.6) 0.0018 0.756
Pathology Classification
Differentiated 60.7 (59.6–61.9) 64.2 (62.3–66.2) 97 (91.6–102.4) 126 (114.1–137.9) 0.0025 0.097
Undifferentiated 37.3 (35.6–39.1) 48.5 (46.3–50.7) 27 (24.6–29.3) 53 (40.6–65.4) <0.001 <0.001
Clinical Stage
Localized without LNM 76.3 (75.2–77.4) 81.7 (80.2–83.3) 142 (–) <0.001 <0.001
Localized with LNM 51.81 (49.0–54.8) 58.88 (54.6–63.6) 65 (56.6–73.4) 111 (78.5–143.5) 0.0026 0.084
Adjacent organ invasion 29.68 (27.2–32.4) 31.6 (28.1–35.6) 26 (23.8–28.2) 25 (22.0–27.9) 0.55 0.433
Distant metastasis 4.45 (3.59–5.51) 5.23 (3.85–7.11) 7 (6.5–7.5) 6 (5.3–6.7) 0.179 0.006

OS: overall survival; MST: Median survival time.

HHS Vulnerability Disclosure